Notice for cemiplimab (Sanofi-Aventis Australia Pty Ltd)
Active ingredients
cemiplimab
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Indication
For the treatment of patients with recurrent or metastatic cervical cancer who have progressed on or after chemotherapy.
Therapeutic area
Oncology